Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Surgical Endoscopy
Published in: Surgical Endoscopy 8/2009

01-08-2009 | Letter

Laparoscopic gastrectomy for organ-confined cancer: a reality in the west?

Authors: Ernst Hanisch, Dimosthenis Ziogas

Published in: Surgical Endoscopy | Issue 8/2009

Login to get access

Excerpt

Open gastrectomy with extended (D2) lymphadenectomy for the treatment of resectable gastric cancer has become the de facto standard of care in Japan and Korea. Excellent outcomes for advanced stages of this disease have reported recently from a high-quality, multicenter, phase III, randomized, controlled trial at 24 hospitals in Japan [1]. Sasako et al. reported a 5-year survival rate of 70% with extended lymphadenectomy for Japanese stages II and III disease without adjuvant treatment [1]. Yet, these results represent a dream for the real western world [2]. Even in specialized institutions in the west, 5-year survival rate for these advanced stages is reported to be less than 40%, and notably these data are derived from nonrandomized studies [3‐7]. …
Literature
1.
Sasako M, Sano T, Yamamoto S, for Japan Clinical Oncology Group et al (2008) D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359:453–462PubMedCrossRef
2.
Roukos DH, Kappas AM (2005) Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2:98–107PubMedCrossRef
3.
Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM (2001) Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 84:1602–1609PubMedCrossRef
4.
Roukos DH, Kappas AM (2002) Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 81:59–62PubMedCrossRef
5.
Kappas AM, Fatouros M, Roukos DH (2004) Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 11:727–730PubMedCrossRef
6.
Roukos DH (1998) Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 80:16–24PubMed
7.
Roukos DH (2000) Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 7:253–255PubMedCrossRef
8.
Kim YW, Baik YH, Yun YH, Nam BH, Kim DH, Choi IJ, Bae JM (2008) Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. Ann Surg 248:721–727PubMedCrossRef
9.
Kim W, Song KY, Lee HJ, Han SU, Hyung WJ, Cho GS (2008) The impact of comorbidity on surgical outcomes in laparoscopy-assisted distal gastrectomy: a retrospective analysis of multicenter results. Ann Surg 248:793–799PubMedCrossRef
10.
Lee JH, Yom CK, Han HS (2008) Comparison of long-term outcomes of laparoscopy-assisted and open distal gastrectomy for early gastric cancer. Surg Endosc, Dec 5 [Epub ahead of print]
11.
Sarela AI (2009) Entirely laparoscopic radical gastrectomy for adenocarcinoma: lymph node yield and resection margins. Surg Endosc 23:153–160PubMedCrossRef
12.
Liakakos T, Roukos DH (2008) More controversy than ever: challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 15:956–960PubMedCrossRef
13.
Kappas AM, Roukos DH (2002) Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol 9:828–830PubMedCrossRef
14.
Roukos DH, Murray S, Briasoulis E (2007) Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 6:308–312PubMedCrossRef
15.
Roukos DH, Lorenz M, Encke A (1998) Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 123:573–578PubMedCrossRef
16.
Roukos DH, Hottenrott C, Encke A, Baltogiannis G, Casioumis D (1994) Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 3:115–125PubMedCrossRef
17.
18.
Ziogas D, Baltogiannis G, Fatouros M, Roukos DH (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247:714–715PubMedCrossRef
19.
Roukos DH (2009) Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9:1–6PubMedCrossRef
20.
Roukos DH, Briasoulis E (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 4:578–590PubMedCrossRef
21.
Agnantis NJ, Paraskevaidis E, Roukos D (2004) Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 11:1030–1034PubMedCrossRef
22.
Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 9:941–943PubMed
23.
Fatouros M, Baltoyiannis G, Roukos DH (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15:21–33PubMedCrossRef
24.
25.
Roukos DH (2007) Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:1555–1556PubMedCrossRef
26.
Roukos DH (2008) Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 8:29–39PubMedCrossRef
27.
Roukos DH (2008) Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn 8:587–597PubMedCrossRef
28.
Roukos DH, Lykoudis E, Liakakos T (2008) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26:4360–4361PubMedCrossRef
29.
Metadata
Title
Laparoscopic gastrectomy for organ-confined cancer: a reality in the west?
Authors
Ernst Hanisch
Dimosthenis Ziogas
Publication date
01-08-2009
Publisher
Springer-Verlag
Published in
Surgical Endoscopy / Issue 8/2009
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-009-0503-6

Other articles of this Issue 8/2009

Surgical Endoscopy 8/2009 Go to the issue

Letter

Robotic D2 surgery for gastric cancer

OriginalPaper

Intralobar sequestration associated with cystic adenomatoid malformation: diagnostic and thoracoscopic pitfalls

OriginalPaper

Preliminary results with a training program for thoracoscopic atrial fibrillation therapy

Letter

Author reply to the letter to the Editor “Robotic D2 surgery for gastric cancer”

OriginalPaper

Effective diameter of balloon dilation for benign esophagojejunal anastomotic stricture after total gastrectomy

OriginalPaper

Safety, feasibility, and short-term outcomes of laparoscopically assisted primary ileocolic resection for Crohn’s disease